FOR ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA IMPROVE OUTCOMES WITH SARCLISA in combination with pomalidomide + dexamethasone (Pd) vs. Pd*1,2

ICARIA-MM: The first positive Phase 3 trial of an anti-CD38 monoclonal antibody triplet in relapsed and refractory multiple myeloma (RRMM)2

SARCLISA + Pd IS NOW REIMBURSED VIA CDF (reference 3)

INDICATION

SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy.

You are now leaving the https://sarclisa.co.uk website.

By clicking on this link, you will be leaving this Sanofi hosted website, and, depending on the link, will be redirected to either another Sanofi website (for example, to view the Sanofi Privacy Policy) or an independent third-party website.
Sanofi has no control over the content or availability of third-party sites or resources that are linked to, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. The existence of a link between this website and any third party site or resource in no way implies that Sanofi in any way approves of the content of these sites or resources, or any use to which such content maybe put.

Please ensure that you read the legal and privacy policy sections of any website to which you link.

CONTINUE